The recent progress in RSV vaccine technology

Recent Patents on Anti-Infective Drug Discovery

Volumn 7, Issue 3, 2012, Pages 237-241

  Fretzayas, Andrew ^a   Papadopoulou, Anna ^a   Kotzia, Doxa ^a   Moustaki, Maria ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adjuvants; DNA vaccines; Live attenuated vaccines; RSV; RSV vaccine; Subunit vaccines

Indexed keywords

ADENOVIRUS VACCINE; DNA VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 5; LIVE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VIRUS PROTEIN;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CODON; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOLOGY; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN DOMAIN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; VIRAL CLEARANCE; VIRUS CAPSID; VIRUS NEUTRALIZATION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; VIRUS SHEDDING;

ANIMALS; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 84870186426     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489112803522002     Document Type: Article

References (43)

1. Breese C, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory synytial virus infection in young children. N Engl J Med 2009; 360: 588-8.
2. Fretzayas A, Moustaki M. The challenges of RSV vaccines. Where do we stand? Recent Pat Antiinfect Drug Discov 2010; 5: 99-107.
3. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem 2008; 389: 521-36.
4. Quan FS, Kim Y, Lee S, Yi H, Kang SM, Bozja J, et al. Virus like particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 2011; 204: 987-95.
5. Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 2010; 84: 1110-23.
6. McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 2011; 85: 366-77.
7. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003; 21: 3406-12.
8. Manickan E, Yu Z, Rouse BT. DNA immunization of neonates induces immunity despite the presence of maternal antibody. J Clin Invest 1997; 100: 2371-5.
9. Li X, Sambhara S, Li CX, Ettorre L, Switzer I, Cates G, James O, et al. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 2000; 269: 54-65.
10. Kumar M, Behera AK, Lockey RF, Zhang J, Bhullar G, De La Cruz CP, et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002; 13: 1415-25.
11. Wu H, Dennis VA, Pillai SR, Singh SR. RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus Res 2009; 145: 39-47.
12. Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F, et al. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 2012; 31: 109-14.
13. Yu JR, Kim S, Lee JB, Chang J. Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection. J Virol 2008; 82: 2350-7.
14. Fu Y, He J, Zheng X, Wu Q, Zhang M, Wang X, et al. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice. Biochem Biophys Res Commun 2009; 381: 528-32.
15. Shao HY, Yu SL, Sia C, Chen Y, Chitra E, Chen IH, et al. Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses. Vaccine 2009; 27: 5460-71.
16. Kohlmann R, Schwannecke S, Tippler B, Ternette N, Temchura VV, Tenbusch M, et al. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol 2009; 83:12601-10.
17. Xie C, He JS, Zhang M, Wu Q, Ding XD, Song W, et al. Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium. Hum Gene Ther 2007; 18: 746-52.
18. Fu YH, He JS, Wang XB, Zheng XX, Wu Q, Xie C, et al. A primeboost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus. Biochem Biophys Res Commun 2010; 395: 87-92.
19. de Waal L, Wyatt LS, Yüksel S, van Amerongen G, Moss B, Niesters HG, et al. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 2004; 22: 923-6.
20. Sawada A, Komase K, Nakayama T. AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats. Vaccine 2011; 29: 1481-90.
21. Mok H, Cheng X, Xu Q, Zengel JR, Parhy B, Zhao J, et al. Evaluation of Measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or epstein-barr virus glycoprotein gp350. Open Virol J 2012; 6: 12-22.
22. Jones BG, Sealy RE, Rudraraju R, Traina-Dorge VL, Finneyfrock B, Cook A, et al. Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine 2012; 30: 959-68.
23. Zhan X, Hurwitz JL, Krishnamurthy S, Takimoto T, Boyd K, Scroggs RA, et al. Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B Vaccine 2007; 25: 8782-93.
24. Slobod KS, Shenep JL, Luján-Zilbermann J, Allison K, Brown B, Scroggs RA, et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004; 22: 3182-6.
25. Elliott MB, Chen T, Terio NB, Chong SY, Abdullah R, Luckay A, et al. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 2007; 25: 7132-44
26. Khan S, Weterings JJ, Britten CM, de Jong AR, Graafland D, Melief CJ, et al. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol Immunol 2009; 46: 1084-91.
27. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440(7085): 808-12.
28. Heit A, Maurer T, Hochrein H, Bauer S, Huster KM, Busch DH, et al. Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J Immunol 2003; 170: 2802-5.
29. Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation. Vaccine 2010; 28: 5543-50.
30. Lindell DM, Morris SB, White MP, Kallal LE, Lundy PK, Hamouda T, et al. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS One 2011; 6: e21823.
31. Alonso-caplen, F., Cutler, M., Fino, M., Pursell, E., Repetto, R. Process for increasing RSV surface glycoprotein yields using a mutant strain of RSV. US7687240B2 (2010).
32. Murata, Y., Rose, R.C., Walsh, E. E, Falsey, A.R. Respiratory synchytial virus vaccine based on chimeric papillomavirus like particles or capsomeres. US0260792 (2010).
33. Pushko, P., Wu, Y., Massare, M., Liu, Y., Smith, G., Zhou, B. Modified RSV F proteins and method of their use. US0239617A1 (2010).
34. Swanson, K., Dormitzer, P.R. RSV F protein composition and methods for making same. US0305727A1 (2011).
35. Chow, Y.H., Liu, S.H., Chong, S.L., HLA A2 restricted T cell epitopes of the RSV fusion protein as peptide based vaccines, US20172925A1 (2010).
36. Chow, Y.H., Sia, C.D.Y., Chong, P.S., Hsia, K.N. Polyvalent chimeric rubella virus-based vaccines. US0272747 (2010).
37. Buchholz, U., Collins, P.L., Murphy, B.R., Whitehead, S.S., Krempl, C.D. Production of human-bovine chimeric RSV vaccines. US7829102B1 (2010).
38. Krempl, C.D., Collins, P.L., Murphy, B.R., Buchholz, U., Whitehead, S.S. RSV vaccines expressing protective antigens from promoter proximal genes. US7662397B2 (2010).
39. Jin, H., Tang, R., Li, S., Bryant, M. Recombinant RSV virus expression systems and vaccines. US0274727A1 (2009).
40. Crowe, J.E., Mok, H., Johnston, R.E., Williams, J.V., Davis, N.L. Vaccine for RSV and MPV. US0162395 A1 (2009).
41. Grundwald, T., Ueberla, K. RSV F protein and its use. US0111989 A1 (2010).
42. Baudoux, G.J., Blais, N., Rheault, P., Ruelle, J.L. Recombinant RSV antigens. US0291147 (2010).
43. Galarza, J.M., Martin, G.R., Chaudhuri, D., Fulvini, A.A. RSV virus like particles. US097358A1 (2011).